ProCE Banner Activity

Clinician’s Guide to Adverse Events Associated With High-Dose Interleukin-2

PDF
Download this PDF for guidance on the safe and effective use of HD IL-2 for patients with renal cell carcinoma.

Released: November 11, 2020

Expiration: November 10, 2021

Share

Faculty

Brendan D. Curti

Brendan D. Curti, MD

Robert W. Franz Endowed Chair for Clinical Research
Earle A. Chiles Research Institute
Providence Cancer Institute
Portland, Oregon

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Clinigen Inc

Faculty Disclosure

Primary Author

Brendan D. Curti, MD

Robert W. Franz Endowed Chair for Clinical Research
Earle A. Chiles Research Institute
Providence Cancer Institute
Portland, Oregon